CDP 860

Drug Profile

CDP 860

Alternative Names: anti-PDGF beta receptor antibody; anti-platelet derived growth factor beta receptor antibody

Latest Information Update: 30 Mar 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Washington; ZymoGenetics
  • Developer Nektar Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Intercellular signalling peptide and protein inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Coronary artery restenosis

Most Recent Events

  • 30 Mar 2004 Discontinued - Phase-II for Cancer in United Kingdom (unspecified route)
  • 16 Jun 2003 CDP 860 is available for partnering (
  • 29 Oct 2002 Inhale Therapeutic Systems and Celltech have entered into a licensing, manufacturing and supply agreement for CDP 860
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top